



Inspired by **patients.**
Driven by **science.**



Jean-Christophe TELLIER

Chief Executive Officer
Chairman of the Executive Committee

Joined UCB in June 2011

Company statement

UCB (www.ucb.com) is a global biopharmaceutical company dedicated to discovering and developing treatments that aim to transform the lives of people living with neurological and immunological conditions in a sustainable way.

Because there is no such thing as an 'average patient' we use the tools, channels and scientific advances at our disposal to develop a deep understanding of a disease and the real needs of patients.

In the last years, the company has brought several innovative drugs to patients across the world: Cimzia[®] (*certolizumab pegol*) in various arthritis indications, Vimpat[®] (*lacosamide*) and Briviact[®] (*brivaracetam*) in epilepsy and Evenity[®] (*romosozumab*) in osteoporosis.

With research collaborations with eminent universities and third parties, UCB enjoys a rich pipeline of future promising drugs and has built one of the most productive R&D organizations in the industry.



Jean-Christophe Tellier

Jean-Christophe Tellier joined UCB in 2011. He became UCB's Chief Executive Officer on January 1, 2015 after having successfully led UCB's BioBrands and Solutions division as Executive Vice President.

He is a member of the Board of Directors of UCB, Chair of BCR (Biopharmaceutical CEOs Roundtable), President IFPMA (International Federation of Pharmaceutical Manufacturers & Associations), Member of the Board of the European Federation of Pharmaceutical Associations (EFPIA) and Vice-Chair of the Innovation Board Sponsored Committee (EFPIA).

He is also a member of the Board of PhRMA (Pharmaceutical Research and Manufacturers of America) and an independent health member of the Supervisory Board of Servier.

Jean-Christophe Tellier is an experienced global leader. He was trained as a Medical Doctor and specialized in rheumatology. He has built a distinguished 30+ year career in the biopharmaceutical industry, taking on different global leadership responsibilities in different parts of the world.

His patient-centric approach, his passion for science, combined with his strategic and operational skills, have allowed him to significantly contribute to UCB's success in recent years. Jean-Christophe believes that the best way to have a positive impact on society and continue to thrive is to deliver on our commitments to patients and our stakeholders. To this end he has led the integration of our sustainability approach into our strategy to help UCB improve its societal impact while ensuring that we continue to perform well as a company.

He has also been instrumental in humanizing UCB's approach towards patients, developing the company's Patient Value Strategy. For Jean-Christophe "engaging the patient in our vision is the best way for our company to be successful in the long term. Having a holistic view of a patient, of his/her life in his/her environment is essential to ensure effective treatment". Jean-Christophe also believes that "all healthcare players - physicians, payors, carers, industry and academia - should cooperate even more effectively and become stronger partners sharing a same goal: improving patient care".

As a leader, Jean-Christophe has always had a passion for developing people, which he sees as "a key force to drive company success". His ambition is to continue to further engage UCB teams behind the company's vision and fully leverage UCB's strong culture and talents

Key positions

Prior to UCB, Jean-Christophe held the following positions:

- | | |
|------|--|
| 2009 | Ipsen:
President and General Manager of Ipsen's North American operations |
| 2008 | MacroGenics: Maryland-based public biotechnology company
Executive Vice President and Chief Commercial Officer |

1989 – 2008

Novartis:

CEO of Novartis Pharma France

CEO of Novartis Pharma Belgium – was President of the Board of the Belgian Pharma Trade association (pharma.be)

Built his career in several local and global marketing and sales positions; was a.o. Head of Novartis' Global Business Franchise in Arthritis, Bone and Muscle Disease

Education

Doctor of Medicine (M.D.) – University of Reims Champagne-Ardenne, France

Post-graduate: Rheumatologist - University of Paris V, France

Executive business programs at Harvard and INSEAD.

